|
US6284727B1
(en)
|
1993-04-07 |
2001-09-04 |
Scios, Inc. |
Prolonged delivery of peptides
|
|
NZ250844A
(en)
|
1993-04-07 |
1996-03-26 |
Pfizer |
Treatment of non-insulin dependant diabetes with peptides; composition
|
|
US5424286A
(en)
|
1993-05-24 |
1995-06-13 |
Eng; John |
Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same
|
|
US5641757A
(en)
|
1994-12-21 |
1997-06-24 |
Ortho Pharmaceutical Corporation |
Stable 2-chloro-2'-deoxyadenosine formulations
|
|
ES2319936T5
(es)
|
1996-08-08 |
2013-06-24 |
Amylin Pharmaceuticals, Inc. |
Regulación de la motilidad gastrointestinal
|
|
US6458924B2
(en)
|
1996-08-30 |
2002-10-01 |
Novo Nordisk A/S |
Derivatives of GLP-1 analogs
|
|
CZ300837B6
(cs)
|
1996-08-30 |
2009-08-26 |
Novo Nordisk A/S |
Deriváty GLP-1(7-37) nebo jeho analogy, farmaceutický prostredek je obsahující a jejich použití
|
|
JP4798814B2
(ja)
|
1997-01-07 |
2011-10-19 |
アミリン・ファーマシューティカルズ，インコーポレイテッド |
食物摂取低減用のエキセンジンおよびそのアゴニストの使用
|
|
US6410511B2
(en)
|
1997-01-08 |
2002-06-25 |
Amylin Pharmaceuticals, Inc. |
Formulations for amylin agonist peptides
|
|
US7312196B2
(en)
|
1997-01-08 |
2007-12-25 |
Amylin Pharmaceuticals, Inc. |
Formulations for amylin agonist peptides
|
|
US6723530B1
(en)
|
1997-02-05 |
2004-04-20 |
Amylin Pharmaceuticals, Inc. |
Polynucleotides encoding proexendin, and methods and uses thereof
|
|
US7157555B1
(en)
|
1997-08-08 |
2007-01-02 |
Amylin Pharmaceuticals, Inc. |
Exendin agonist compounds
|
|
AU749914B2
(en)
|
1997-08-08 |
2002-07-04 |
Amylin Pharmaceuticals, Inc. |
Novel exendin agonist compounds
|
|
NZ504258A
(en)
|
1997-11-14 |
2002-12-20 |
Amylin Pharmaceuticals Inc |
Exendin 3 and 4 agonist compounds for the treatment of diabetes
|
|
EP1032587B2
(en)
|
1997-11-14 |
2013-03-13 |
Amylin Pharmaceuticals, Inc. |
Novel exendin agonist compounds
|
|
US7223725B1
(en)
|
1997-11-14 |
2007-05-29 |
Amylin Pharmaceuticals, Inc. |
Exendin agonist compounds
|
|
US7220721B1
(en)
|
1997-11-14 |
2007-05-22 |
Amylin Pharmaceuticals, Inc. |
Exendin agonist peptides
|
|
JP4353544B2
(ja)
|
1998-01-09 |
2009-10-28 |
アミリン・ファーマシューティカルズ，インコーポレイテッド |
アミリン作動薬ペプチド用製剤
|
|
US6703359B1
(en)
|
1998-02-13 |
2004-03-09 |
Amylin Pharmaceuticals, Inc. |
Inotropic and diuretic effects of exendin and GLP-1
|
|
WO1999043708A1
(en)
|
1998-02-27 |
1999-09-02 |
Novo Nordisk A/S |
Glp-1 derivatives of glp-1 and exendin with protracted profile of action
|
|
CA2321026A1
(en)
|
1998-03-09 |
1999-09-16 |
Zealand Pharmaceuticals A/S |
Pharmacologically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis
|
|
AU2612599A
(en)
|
1998-03-13 |
1999-10-11 |
Novo Nordisk A/S |
Stabilized aqueous peptide solutions
|
|
US6998387B1
(en)
|
1998-03-19 |
2006-02-14 |
Amylin Pharmaceuticals, Inc. |
Human appetite control by glucagon-like peptide receptor binding compounds
|
|
OA11694A
(en)
|
1998-06-12 |
2005-01-12 |
Bionebraska Inc |
Glucagon-like peptide-1 improves beta-cell response to glucose in subjects with impaired glucose tolerance.
|
|
EP1105460B1
(en)
|
1998-08-10 |
2009-10-07 |
THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES |
Differentiation of non-insulin producing cells into insulin producing cells by glp-1 or exendin-4 and uses thereof
|
|
AU765584B2
(en)
|
1998-09-17 |
2003-09-25 |
Eli Lilly And Company |
Protein formulations
|
|
US6284725B1
(en)
|
1998-10-08 |
2001-09-04 |
Bionebraska, Inc. |
Metabolic intervention with GLP-1 to improve the function of ischemic and reperfused tissue
|
|
US6429197B1
(en)
|
1998-10-08 |
2002-08-06 |
Bionebraska, Inc. |
Metabolic intervention with GLP-1 or its biologically active analogues to improve the function of the ischemic and reperfused brain
|
|
US7259136B2
(en)
|
1999-04-30 |
2007-08-21 |
Amylin Pharmaceuticals, Inc. |
Compositions and methods for treating peripheral vascular disease
|
|
DK1140148T3
(da)
|
1998-12-22 |
2006-01-30 |
Lilly Co Eli |
Lagerholdbar formulering af glucagon-agtigt peptid-1
|
|
DK1140145T4
(da)
|
1999-01-14 |
2019-07-22 |
Amylin Pharmaceuticals Llc |
Hidtil ukendte exendinagonistformuleringer og fremgangsmåder til indgivelse deraf
|
|
US20030087820A1
(en)
|
1999-01-14 |
2003-05-08 |
Young Andrew A. |
Novel exendin agonist formulations and methods of administration thereof
|
|
ES2343072T3
(es)
|
1999-01-14 |
2010-07-22 |
Amylin Pharmaceuticals, Inc. |
Exendina para la supresion del glucagon.
|
|
US7399489B2
(en)
|
1999-01-14 |
2008-07-15 |
Amylin Pharmaceuticals, Inc. |
Exendin analog formulations
|
|
PL351326A1
(en)
|
1999-03-17 |
2003-04-07 |
Novo Nordisk As |
Method for acylating peptides and novel acylating agents
|
|
US6451974B1
(en)
|
1999-03-17 |
2002-09-17 |
Novo Nordisk A/S |
Method of acylating peptides and novel acylating agents
|
|
NZ514916A
(en)
|
1999-04-30 |
2004-06-25 |
Amylin Pharmaceuticals Inc |
Exendins and exendin agonists linked to polyethylene glycol polymers
|
|
US6924264B1
(en)
|
1999-04-30 |
2005-08-02 |
Amylin Pharmaceuticals, Inc. |
Modified exendins and exendin agonists
|
|
US6849714B1
(en)
|
1999-05-17 |
2005-02-01 |
Conjuchem, Inc. |
Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
|
|
CN1191273C
(zh)
|
1999-05-17 |
2005-03-02 |
康久化学公司 |
长效促胰岛肽
|
|
US6514500B1
(en)
|
1999-10-15 |
2003-02-04 |
Conjuchem, Inc. |
Long lasting synthetic glucagon like peptide {GLP-!}
|
|
US6887470B1
(en)
|
1999-09-10 |
2005-05-03 |
Conjuchem, Inc. |
Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
|
|
US6482799B1
(en)
|
1999-05-25 |
2002-11-19 |
The Regents Of The University Of California |
Self-preserving multipurpose ophthalmic solutions incorporating a polypeptide antimicrobial
|
|
US6506724B1
(en)
|
1999-06-01 |
2003-01-14 |
Amylin Pharmaceuticals, Inc. |
Use of exendins and agonists thereof for the treatment of gestational diabetes mellitus
|
|
US6344180B1
(en)
|
1999-06-15 |
2002-02-05 |
Bionebraska, Inc. |
GLP-1 as a diagnostic test to determine β-cell function and the presence of the condition of IGT and type II diabetes
|
|
US6528486B1
(en)
|
1999-07-12 |
2003-03-04 |
Zealand Pharma A/S |
Peptide agonists of GLP-1 activity
|
|
US6972319B1
(en)
|
1999-09-28 |
2005-12-06 |
Bayer Pharmaceuticals Corporation |
Pituitary adenylate cyclase activating peptide (PACAP)receptor 3 (R3) agonists and their pharmacological methods of use
|
|
GB9930882D0
(en)
|
1999-12-30 |
2000-02-23 |
Nps Allelix Corp |
GLP-2 formulations
|
|
EP1246638B2
(en)
|
2000-01-10 |
2014-07-30 |
Amylin Pharmaceuticals, Inc. |
Use of exendins and agonists thereof for the treatment of hypertriglyceridemia
|
|
EP1267912A2
(en)
|
2000-03-14 |
2003-01-02 |
Burkhard Göke |
Effects of glucagon-like peptide-1 (7-36) on antro-pyloro-duodenal motility
|
|
WO2001087322A2
(en)
|
2000-05-17 |
2001-11-22 |
Bionebraska, Inc. |
Peptide pharmaceutical formulations
|
|
KR100518046B1
(ko)
|
2000-05-19 |
2005-10-04 |
아밀린 파마슈티칼스, 인크. |
Ｇｌｐ-1을 사용한 급성 관상동맥 증후군의 치료
|
|
AU2001284985A1
(en)
|
2000-08-18 |
2002-03-04 |
Emisphere Technologies, Inc. |
Compounds and compositions for delivering active agents
|
|
US7507714B2
(en)
|
2000-09-27 |
2009-03-24 |
Bayer Corporation |
Pituitary adenylate cyclase activating peptide (PACAP) receptor 3 (R3) agonists and their pharmacological methods of use
|
|
US6894024B2
(en)
|
2000-10-20 |
2005-05-17 |
Amylin Pharmaceuticals, Inc. |
Treatment of hibernating myocardium and diabetic cardiomyopathy with a GLP-1 peptide
|
|
MXPA03005036A
(es)
|
2000-12-07 |
2003-09-05 |
Lilly Co Eli |
Proteinas de fusion glp-1.
|
|
AU2002239384B2
(en)
|
2000-12-13 |
2007-01-11 |
Eli Lilly And Company |
Chronic treatment regimen using glucagon-like insulinotropic peptides
|
|
GB2371227A
(en)
|
2001-01-10 |
2002-07-24 |
Grandis Biotech Gmbh |
Crystallisation - resistant aqueous growth hormone formulations
|
|
US6573237B2
(en)
|
2001-03-16 |
2003-06-03 |
Eli Lilly And Company |
Protein formulations
|
|
CN1162446C
(zh)
|
2001-05-10 |
2004-08-18 |
上海华谊生物技术有限公司 |
促胰岛素分泌肽衍生物
|
|
EP1542712A2
(en)
|
2001-06-01 |
2005-06-22 |
Eli Lilly And Company |
Glp-1 formulations with protracted time action
|
|
WO2003002136A2
(en)
|
2001-06-28 |
2003-01-09 |
Novo Nordisk A/S |
Stable formulation of modified glp-1
|
|
JP3935487B2
(ja)
|
2001-07-16 |
2007-06-20 |
フーベルト・ケスター |
捕獲化合物、その収集物、ならびにプロテオームおよび複合組成物の分析方法
|
|
AU2002317599B2
(en)
|
2001-07-31 |
2008-04-03 |
The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services |
GLP-1 exendin-4 peptide analogs and uses thereof
|
|
CA2452044A1
(en)
|
2001-08-28 |
2003-03-13 |
Eli Lilly And Company |
Pre-mixes of glp-1 and basal insulin
|
|
MXPA04003569A
(es)
|
2001-10-19 |
2004-07-23 |
Lilly Co Eli |
Mezclas bifasicas de glp-1 e insulina.
|
|
EP2277910A1
(en)
|
2001-12-21 |
2011-01-26 |
Human Genome Sciences, Inc. |
Albumin fusion proteins
|
|
EP1463752A4
(en)
|
2001-12-21 |
2005-07-13 |
Human Genome Sciences Inc |
ALBUMIN FUSION PROTEINS
|
|
US7105489B2
(en)
|
2002-01-22 |
2006-09-12 |
Amylin Pharmaceuticals, Inc. |
Methods and compositions for treating polycystic ovary syndrome
|
|
MXPA04008068A
(es)
|
2002-02-20 |
2004-11-26 |
Lilly Co Eli |
Metodo para administrar moleculas de glp-1.
|
|
EP1478394B1
(en)
|
2002-02-27 |
2008-07-30 |
Immunex Corporation |
Stabilized TNFR-Fc composition comprising arginine
|
|
EP1502102B1
(en)
|
2002-03-11 |
2009-01-14 |
caprotec bioanalytics GmbH |
Compounds and methods for analyzing the proteome
|
|
US7141240B2
(en)
|
2002-03-12 |
2006-11-28 |
Cedars-Sinai Medical Center |
Glucose-dependent insulin-secreting cells transfected with a nucleotide sequence encoding GLP-1
|
|
AU2003226913A1
(en)
|
2002-04-04 |
2003-10-20 |
Novo Nordisk A/S |
Glp-1 agonist and cardiovascular complications
|
|
NZ535684A
(en)
|
2002-04-10 |
2006-03-31 |
Lilly Co Eli |
Use of a GLP-1 (glucagon like peptide-1) compound to treat gastroparesis by increasing gastric emptying
|
|
US6861236B2
(en)
|
2002-05-24 |
2005-03-01 |
Applied Nanosystems B.V. |
Export and modification of (poly)peptides in the lantibiotic way
|
|
EP1515749B1
(en)
|
2002-06-14 |
2012-08-15 |
Novo Nordisk A/S |
Combined use of a modulator of cd3 and a glp-1 compound
|
|
US20040037826A1
(en)
|
2002-06-14 |
2004-02-26 |
Michelsen Birgitte Koch |
Combined use of a modulator of CD3 and a GLP-1 compound
|
|
DE10227232A1
(de)
|
2002-06-18 |
2004-01-15 |
Aventis Pharma Deutschland Gmbh |
Saure Insulinzubereitungen mit verbesserter Stabilität
|
|
ES2327328T3
(es)
|
2002-07-04 |
2009-10-28 |
Zealand Pharma A/S |
Glp-1 y procedimientos para el tratamiento de la diabetes.
|
|
US20070065469A1
(en)
|
2002-07-09 |
2007-03-22 |
Michael Betz |
Liquid formulations with high concentration of human growth hormone (high) comprising glycine
|
|
AR040529A1
(es)
|
2002-07-09 |
2005-04-13 |
Grandis Biotech Gmbh |
Formulaciones de hgh en alta concentracion que contienen 1,2-propilenglicol
|
|
US20080260838A1
(en)
|
2003-08-01 |
2008-10-23 |
Mannkind Corporation |
Glucagon-like peptide 1 (glp-1) pharmaceutical formulations
|
|
US20040038865A1
(en)
|
2002-08-01 |
2004-02-26 |
Mannkind Corporation |
Cell transport compositions and uses thereof
|
|
CA2493478C
(en)
|
2002-08-01 |
2014-11-18 |
Mannkind Corporation |
Cell transport compositions and uses thereof
|
|
US7407955B2
(en)
|
2002-08-21 |
2008-08-05 |
Boehringer Ingelheim Pharma Gmbh & Co., Kg |
8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
|
|
EP2308878A3
(de)
|
2002-08-21 |
2011-10-26 |
Boehringer Ingelheim Pharma GmbH & Co. KG |
8-[3-Amino-Piperidin-1-YL] -Xanthine, deren Herstellung und deren Verwendung als Arzneimittel
|
|
KR20050083713A
(ko)
|
2002-10-02 |
2005-08-26 |
질랜드 파마 에이/에스 |
안정화된 엑센딘-4 화합물
|
|
US20050209142A1
(en)
|
2002-11-20 |
2005-09-22 |
Goran Bertilsson |
Compounds and methods for increasing neurogenesis
|
|
US20050009847A1
(en)
|
2002-11-20 |
2005-01-13 |
Goran Bertilsson |
Compounds and methods for increasing neurogenesis
|
|
US6969702B2
(en)
|
2002-11-20 |
2005-11-29 |
Neuronova Ab |
Compounds and methods for increasing neurogenesis
|
|
EP1610811A4
(en)
|
2002-12-17 |
2008-03-26 |
Amylin Pharmaceuticals Inc |
PREVENTION AND TREATMENT OF CARDIAC ARRHYTHMIAS
|
|
US7790681B2
(en)
|
2002-12-17 |
2010-09-07 |
Amylin Pharmaceuticals, Inc. |
Treatment of cardiac arrhythmias with GLP-1 receptor ligands
|
|
US20040209803A1
(en)
|
2002-12-19 |
2004-10-21 |
Alain Baron |
Compositions for the treatment and prevention of nephropathy
|
|
GB0300571D0
(en)
|
2003-01-10 |
2003-02-12 |
Imp College Innovations Ltd |
Modification of feeding behaviour
|
|
PL1620118T3
(pl)
|
2003-04-08 |
2014-11-28 |
Yeda Res & Dev |
Leki odwracalnie pegylowane
|
|
WO2004089985A1
(en)
|
2003-04-11 |
2004-10-21 |
Novo Nordisk A/S |
Stable pharmaceutical compositions
|
|
EP1633384B1
(en)
|
2003-05-15 |
2012-03-14 |
Trustees Of Tufts College |
Stable analogs of glp-1
|
|
US7947261B2
(en)
|
2003-05-23 |
2011-05-24 |
Nektar Therapeutics |
Conjugates formed from polymer derivatives having particular atom arrangements
|
|
CN1747748B
(zh)
|
2003-05-23 |
2011-01-19 |
尼克塔治疗公司 |
具有特定原子排列的聚合物衍生物
|
|
EP1631308B1
(en)
|
2003-05-30 |
2013-07-31 |
Amylin Pharmaceuticals, LLC |
Novel methods and compositions for enhanced transmucosal delivery of peptides and proteins
|
|
AU2004243531B2
(en)
|
2003-06-03 |
2009-11-05 |
Novo Nordisk A/S |
Stabilized pharmaceutical peptide compositions
|
|
ATE529126T1
(de)
|
2003-06-03 |
2011-11-15 |
Novo Nordisk As |
Stabilisierte pharmazeutische peptid zusammensetzungen
|
|
EP2292254A3
(en)
|
2003-06-03 |
2011-12-14 |
Novo Nordisk A/S |
Stabilized pharmaceutical peptide compositions
|
|
EP1633391B1
(en)
|
2003-06-03 |
2011-10-19 |
Novo Nordisk A/S |
Stabilized pharmaceutical peptide compositions
|
|
US8921311B2
(en)
|
2003-08-01 |
2014-12-30 |
Mannkind Corporation |
Method for treating hyperglycemia
|
|
JP4463814B2
(ja)
|
2003-08-05 |
2010-05-19 |
ノボ ノルディスク アクティーゼルスカブ |
新規のインスリン誘導体
|
|
EP1664108B1
(en)
|
2003-08-21 |
2009-10-14 |
Novo Nordisk A/S |
Separation of polypeptides comprising a racemized amino acid
|
|
EP1663295A2
(en)
|
2003-09-01 |
2006-06-07 |
Novo Nordisk A/S |
Stable formulations of peptides
|
|
US20060247167A1
(en)
|
2003-09-01 |
2006-11-02 |
Novo Nordisk A/S |
Stable formulations of peptides
|
|
JP2007537981A
(ja)
|
2003-09-19 |
2007-12-27 |
ノボ ノルディスク アクティーゼルスカブ |
新規の血漿タンパク質親和性タグ
|
|
US20060287221A1
(en)
|
2003-11-13 |
2006-12-21 |
Novo Nordisk A/S |
Soluble pharmaceutical compositions for parenteral administration comprising a GLP-1 peptide and an insulin peptide of short time action for treatment of diabetes and bulimia
|
|
ATE525083T1
(de)
|
2003-11-13 |
2011-10-15 |
Novo Nordisk As |
Pharmazeutische zusammensetzung umfassend eine insulinotrope glp-1(7-37) analoge, asp(b28)- insulin, und eine oberflächenaktive verbindung
|
|
US20050281879A1
(en)
|
2003-11-14 |
2005-12-22 |
Guohua Chen |
Excipients in drug delivery vehicles
|
|
US20050106214A1
(en)
|
2003-11-14 |
2005-05-19 |
Guohua Chen |
Excipients in drug delivery vehicles
|
|
CN1882356B
(zh)
|
2003-11-20 |
2015-02-25 |
诺沃挪第克公司 |
对于生产和用于注射装置中是最佳的含有丙二醇的肽制剂
|
|
WO2005081619A2
(en)
|
2003-11-20 |
2005-09-09 |
Neuronova Ab |
Compounds and methods for increasing neurogenesis
|
|
JP5697831B2
(ja)
|
2003-12-03 |
2015-04-08 |
ノヴォ ノルディスク アー／エス |
単鎖インシュリン
|
|
EP1691841B1
(en)
|
2003-12-10 |
2020-09-09 |
Nektar Therapeutics |
Compositions comprising two different populations of polymer-active agent conjugates
|
|
US20060210614A1
(en)
|
2003-12-26 |
2006-09-21 |
Nastech Pharmaceutical Company Inc. |
Method of treatment of a metabolic disease using intranasal administration of exendin peptide
|
|
US20050143303A1
(en)
|
2003-12-26 |
2005-06-30 |
Nastech Pharmaceutical Company Inc. |
Intranasal administration of glucose-regulating peptides
|
|
CN1938334A
(zh)
|
2004-01-30 |
2007-03-28 |
瓦拉塔药品公司 |
Glp－1激动剂和胃泌素化合物的联合使用
|
|
IN2012DN03921A
(enExample)
|
2004-02-11 |
2015-09-04 |
Amylin Pharmaceuticals Inc |
|
|
EP2233497A3
(en)
|
2004-02-11 |
2011-01-12 |
Amylin Pharmaceuticals, Inc. |
Amylin family peptides and methods for making and using them
|
|
EP1789440A4
(en)
|
2004-02-11 |
2008-03-12 |
Amylin Pharmaceuticals Inc |
REASONS FOR THE FAMILY OF PANCREATIC POLYPEPTIDES AND POLYPEPTIDES CONTAINING THEM
|
|
US8076288B2
(en)
|
2004-02-11 |
2011-12-13 |
Amylin Pharmaceuticals, Inc. |
Hybrid polypeptides having glucose lowering activity
|
|
US7399744B2
(en)
|
2004-03-04 |
2008-07-15 |
Amylin Pharmaceuticals, Inc. |
Methods for affecting body composition
|
|
US7456254B2
(en)
|
2004-04-15 |
2008-11-25 |
Alkermes, Inc. |
Polymer-based sustained release device
|
|
US20060110423A1
(en)
|
2004-04-15 |
2006-05-25 |
Wright Steven G |
Polymer-based sustained release device
|
|
CN1968700A
(zh)
|
2004-04-15 |
2007-05-23 |
阿尔克姆斯有限公司 |
聚合物基的持续释放装置
|
|
WO2005117584A2
(en)
|
2004-05-28 |
2005-12-15 |
Amylin Pharmaceuticals, Inc |
Improved transmucosal delivery of peptides and proteins
|
|
US20090069226A1
(en)
|
2004-05-28 |
2009-03-12 |
Amylin Pharmaceuticals, Inc. |
Transmucosal delivery of peptides and proteins
|
|
JP2008501765A
(ja)
|
2004-06-11 |
2008-01-24 |
ノボ ノルディスク アクティーゼルスカブ |
Ｇｌｐ−１アゴニストを用いた薬剤誘発性肥満の中和
|
|
CN103223160B
(zh)
|
2004-07-19 |
2015-02-18 |
比奥孔有限公司 |
胰岛素-低聚物共轭物,制剂及其用途
|
|
EP1771573A4
(en)
|
2004-07-21 |
2009-02-18 |
Ambrx Inc |
BIOSYNTHETIC POLYPEPTIDES OBTAINED FROM NON-NATURALLY CITED AMINO ACIDS
|
|
MX2007001424A
(es)
|
2004-08-03 |
2008-03-13 |
Biorexis Pharmaceutical Corp |
Terapia de combinacion usando proteinas de fusion a transferrina que comprenden peptido 1 tipo glucagon.
|
|
ES2442223T3
(es)
|
2004-08-31 |
2014-02-10 |
Novo Nordisk A/S |
Uso de tris(hidroximetil) aminometano para la estabilización de péptidos, polipéptidos y proteínas
|
|
DE102004043153B4
(de)
|
2004-09-03 |
2013-11-21 |
Philipps-Universität Marburg |
Erfindung betreffend GLP-1 und Exendin
|
|
WO2006029634A2
(en)
|
2004-09-17 |
2006-03-23 |
Novo Nordisk A/S |
Pharmaceutical compositions containing insulin and insulinotropic peptide
|
|
EP3173072A1
(en)
|
2004-10-01 |
2017-05-31 |
Ramscor, Inc. |
Conveniently implantable sustained release drug compositions
|
|
EP1799711B1
(en)
|
2004-10-07 |
2012-06-20 |
Novo Nordisk A/S |
Protracted exendin-4 compounds
|
|
US7595294B2
(en)
|
2004-10-08 |
2009-09-29 |
Transition Therapeutics, Inc. |
Vasoactive intestinal polypeptide pharmaceuticals
|
|
WO2006044531A2
(en)
|
2004-10-13 |
2006-04-27 |
Isis Parmaceuticals, Inc. |
Antisense modulation of ptp1b expression
|
|
US7442682B2
(en)
|
2004-10-19 |
2008-10-28 |
Nitto Denko Corporation |
Transepithelial delivery of peptides with incretin hormone activities
|
|
CN106137952B
(zh)
|
2004-11-12 |
2020-11-17 |
诺和诺德公司 |
促胰岛素肽的稳定制剂
|
|
US20080125361A1
(en)
|
2004-11-12 |
2008-05-29 |
Novo Nordisk A/S |
Stable Formulations Of Peptides
|
|
US20090011976A1
(en)
|
2004-11-12 |
2009-01-08 |
Novo Nordisk A/S |
Stable Formulations Of Peptides
|
|
WO2006059106A2
(en)
|
2004-12-02 |
2006-06-08 |
Domantis Limited |
Bispecific domain antibodies targeting serum albumin and glp-1 or pyy
|
|
JP5743371B2
(ja)
|
2004-12-13 |
2015-07-01 |
アミリン・ファーマシューティカルズ, リミテッド・ライアビリティ・カンパニーAmylin Pharmaceuticals, Llc |
膵臓ポリペプチドファミリーモチーフ、ポリペプチドおよびこれらを含む方法
|
|
ATE494012T1
(de)
|
2004-12-21 |
2011-01-15 |
Nektar Therapeutics |
Stabilisierte polymer-thiol-reagenzien
|
|
SI1831252T1
(sl)
|
2004-12-22 |
2009-12-31 |
Lilly Co Eli |
Formulacije analogov glp-1 fuzijskih proteinov
|
|
CA2599594A1
(en)
|
2004-12-24 |
2006-07-13 |
Amylin Pharmaceuticals, Inc. |
Use of glp-1 and agonists thereof to prevent cardiac myocyte apoptosis
|
|
US8716221B2
(en)
|
2005-01-14 |
2014-05-06 |
Wuxi Grandchamp Pharmaceutical Technology Co., Ltd. |
Modified exendins and uses thereof
|
|
CA2603630C
(en)
|
2005-01-14 |
2015-06-09 |
Wuxi Grandchamp Pharmaceutical Technology Co., Ltd. |
Modified exendins and uses thereof
|
|
US20080233053A1
(en)
|
2005-02-07 |
2008-09-25 |
Pharmalight Inc. |
Method and Device for Ophthalmic Administration of Active Pharmaceutical Ingredients
|
|
US8263545B2
(en)
|
2005-02-11 |
2012-09-11 |
Amylin Pharmaceuticals, Inc. |
GIP analog and hybrid polypeptides with selectable properties
|
|
WO2006086769A2
(en)
|
2005-02-11 |
2006-08-17 |
Amylin Pharmaceuticals, Inc. |
Gip analog and hybrid polypeptides with selectable properties
|
|
WO2006097535A2
(en)
|
2005-03-18 |
2006-09-21 |
Novo Nordisk A/S |
Peptide agonists of the glucagon family with secretin like activity
|
|
DK1888103T3
(da)
|
2005-04-11 |
2012-04-23 |
Amylin Pharmaceuticals Inc |
Anvendelse af glp-1, exendin og agonister deraf til forsinkelse eller forhindring af kardial remodellering
|
|
US20090043264A1
(en)
|
2005-04-24 |
2009-02-12 |
Novo Nordisk A/S |
Injection Device
|
|
US8097584B2
(en)
|
2005-05-25 |
2012-01-17 |
Novo Nordisk A/S |
Stabilized formulations of insulin that comprise ethylenediamine
|
|
WO2006127948A2
(en)
|
2005-05-26 |
2006-11-30 |
Bristol-Myers Squibb Company |
N-terminally modified glp-1 receptor modulators
|
|
CA2609810C
(en)
|
2005-06-06 |
2012-05-22 |
Camurus Ab |
Glp-1 analogue formulations
|
|
GB0511986D0
(en)
|
2005-06-13 |
2005-07-20 |
Imp College Innovations Ltd |
Novel compounds and their effects on feeding behaviour
|
|
SI1891105T1
(sl)
*
|
2005-06-13 |
2012-07-31 |
Imp Innovations Ltd |
Analogi oksintomodulina in njihovi učinki na prehranjevalno vedenje
|
|
WO2006138572A2
(en)
|
2005-06-16 |
2006-12-28 |
Nektar Therapeutics Al, Corporation |
Conjugates having a degradable linkage and polymeric reagents useful in preparing such conjugates
|
|
MX2008001706A
(es)
|
2005-08-04 |
2008-04-07 |
Nektar Therapeutics Al Corp |
Conjugados de una porcion g-csf y un polimero.
|
|
WO2007016764A1
(en)
|
2005-08-06 |
2007-02-15 |
Qinghua Wang |
Composition and method for prevention and treatment of type i diabetes
|
|
AU2006279680B2
(en)
|
2005-08-11 |
2012-12-06 |
Amylin Pharmaceuticals, Llc |
Hybrid polypeptides with selectable properties
|
|
JP5693817B2
(ja)
|
2005-08-19 |
2015-04-01 |
アミリン・ファーマシューティカルズ, リミテッド・ライアビリティ・カンパニーAmylin Pharmaceuticals, Llc |
糖尿病の治療法および体重の減少法
|
|
WO2007033372A2
(en)
|
2005-09-14 |
2007-03-22 |
Mannkind Corporation |
Method of drug formulation based on increasing the affinity of crystalline microparticle surfaces for active agents
|
|
US8143217B2
(en)
|
2005-09-20 |
2012-03-27 |
Novartis Ag |
Use of DPP-IV inhibitor to reduce hypoglycemic events
|
|
WO2007047834A2
(en)
|
2005-10-18 |
2007-04-26 |
Biocon Limited |
Oral peptide conjugates for metabolic diseases
|
|
WO2007047997A2
(en)
|
2005-10-19 |
2007-04-26 |
Smartcells, Inc. |
Methods for reducing the mitogenicity of lectin compositions
|
|
CN101534846B
(zh)
|
2005-11-07 |
2014-11-05 |
印第安纳大学研究及科技有限公司 |
显示生理学溶解性和稳定性的胰高血糖素类似物
|
|
US8039432B2
(en)
|
2005-11-09 |
2011-10-18 |
Conjuchem, Llc |
Method of treatment of diabetes and/or obesity with reduced nausea side effect
|
|
MX2008007075A
(es)
|
2005-12-02 |
2008-11-12 |
Mdrna Inc |
Formulacion farmaceutica para incrementar la permeabilidad epitelial por peptido regulador de glucosa.
|
|
EP1968607B1
(en)
|
2005-12-02 |
2014-01-15 |
Nabil Habib Lab |
Treatment of cancer and other diseases
|
|
EP1959987A2
(en)
|
2005-12-08 |
2008-08-27 |
Nastech Pharmaceutical Company Inc. |
Mucosal delivery of stabilized formulations of exendin
|
|
WO2007075534A2
(en)
|
2005-12-16 |
2007-07-05 |
Nektar Therapeutics Al, Corporation |
Polymer conjugates of glp-1
|
|
ES2779992T3
(es)
|
2005-12-20 |
2020-08-21 |
Univ Duke |
Métodos y composiciones para suministrar agentes activos con propiedades farmacológicas potenciadas
|
|
US8841255B2
(en)
|
2005-12-20 |
2014-09-23 |
Duke University |
Therapeutic agents comprising fusions of vasoactive intestinal peptide and elastic peptides
|
|
US20130172274A1
(en)
|
2005-12-20 |
2013-07-04 |
Duke University |
Methods and compositions for delivering active agents with enhanced pharmacological properties
|
|
RU2427383C2
(ru)
|
2006-01-18 |
2011-08-27 |
КьюПиЭс, ЭлЭлСи |
Фармацевтические композиции с повышенной стабильностью
|
|
WO2007092772A2
(en)
|
2006-02-03 |
2007-08-16 |
Medimmune, Inc. |
Protein formulations
|
|
US7704953B2
(en)
|
2006-02-17 |
2010-04-27 |
Mdrna, Inc. |
Phage displayed cell binding peptides
|
|
WO2007109354A2
(en)
|
2006-03-21 |
2007-09-27 |
Amylin Pharmaceuticals, Inc. |
Peptide-peptidase inhibitor conjugates and methods of using same
|
|
MX2008013168A
(es)
|
2006-04-13 |
2008-10-27 |
Sod Conseils Rech Applic |
Composiciones faramaceuticas del peptido 1 similar al glucagon humano, exendina-4 y análogos de los mismos.
|
|
BRPI0709964A2
(pt)
|
2006-04-14 |
2011-08-02 |
Mannkind Corp |
formulações farmacêuticas contendo peptìdeo glucagon do tipo 1 (glp-1)
|
|
PE20110235A1
(es)
|
2006-05-04 |
2011-04-14 |
Boehringer Ingelheim Int |
Combinaciones farmaceuticas que comprenden linagliptina y metmorfina
|
|
WO2007133778A2
(en)
|
2006-05-12 |
2007-11-22 |
Amylin Pharmaceuticals, Inc. |
Methods to restore glycemic control
|
|
WO2007139589A1
(en)
|
2006-05-26 |
2007-12-06 |
Bristol-Myers Squibb Company |
Sustained release glp-1 receptor modulators
|
|
WO2007139941A2
(en)
|
2006-05-26 |
2007-12-06 |
Amylin Pharmaceuticals, Inc. |
Composition and methods for treatment of congestive heart failure
|
|
CN101501209B
(zh)
|
2006-06-21 |
2013-06-05 |
百奥勤有限公司 |
具有促胰岛素活性的生物活性多肽的制备方法
|
|
EP2051697A2
(en)
|
2006-07-05 |
2009-04-29 |
Foamix Ltd. |
Foamable vehicle comprising dicarboxylic acid or dicarboxylic acid ester and pharmaceutical compositions thereof
|
|
JP5102833B2
(ja)
|
2006-07-24 |
2012-12-19 |
バイオレクシス ファーマシューティカル コーポレーション |
エキセンディン融合タンパク質
|
|
US7928186B2
(en)
|
2006-08-02 |
2011-04-19 |
Phoenix Pharmaceuticals, Inc. |
Cell permeable bioactive peptide conjugates
|
|
EP2046284A1
(en)
|
2006-08-04 |
2009-04-15 |
Nastech Pharmaceutical Company Inc. |
Compositions for intranasal delivery of human insulin and uses thereof
|
|
AU2007284759B2
(en)
|
2006-08-09 |
2010-10-28 |
Intarcia Therapeutics, Inc. |
Osmotic delivery systems and piston assemblies
|
|
US8497240B2
(en)
|
2006-08-17 |
2013-07-30 |
Amylin Pharmaceuticals, Llc |
DPP-IV resistant GIP hybrid polypeptides with selectable properties
|
|
AU2007284365A1
(en)
|
2006-08-17 |
2008-02-21 |
Amylin Pharmaceuticals, Inc. |
DPP-IV resistant GIP hybrid polypeptides with selectable properties
|
|
EP2057189B1
(en)
*
|
2006-08-25 |
2013-03-06 |
Novo Nordisk A/S |
Acylated exendin-4 compounds
|
|
CN101125207B
(zh)
|
2006-11-14 |
2012-09-05 |
上海华谊生物技术有限公司 |
带有聚乙二醇基团的艾塞丁或其类似物及其制剂和用途
|
|
JP2010512399A
(ja)
|
2006-12-12 |
2010-04-22 |
アミリン・ファーマシューティカルズ，インコーポレイテッド |
医薬製剤及びその調製方法
|
|
TWI428346B
(zh)
|
2006-12-13 |
2014-03-01 |
Imp Innovations Ltd |
新穎化合物及其等對進食行為影響
|
|
US20090098130A1
(en)
*
|
2007-01-05 |
2009-04-16 |
Bradshaw Curt W |
Glucagon-like protein-1 receptor (glp-1r) agonist compounds
|
|
RU2432361C2
(ru)
|
2007-01-05 |
2011-10-27 |
КовЭкс Текнолоджиз Айэлэнд Лимитед |
Соединения агонисты рецептора глюкагоноподобного белка-1 (glp-1r)
|
|
CN101663317A
(zh)
|
2007-01-05 |
2010-03-03 |
CovX科技爱尔兰有限公司 |
胰高血糖素样蛋白-1受体glp-1r激动剂化合物
|
|
EP2124974B1
(en)
|
2007-01-05 |
2017-03-15 |
Indiana University Research and Technology Corporation |
Glucagon analogs exhibiting enhanced solubility in physiological ph buffers
|
|
WO2008098212A2
(en)
|
2007-02-08 |
2008-08-14 |
Diobex, Inc. |
Extended release formulations of glucagon and other peptides and proteins
|
|
BRPI0807728A2
(pt)
|
2007-02-15 |
2012-04-17 |
Univ Indiana Res & Tech Corp |
co-agonistas de receptor glucagon/glp-1
|
|
US8420598B2
(en)
|
2007-04-20 |
2013-04-16 |
B & L Delipharm Corp. |
Mono modified exendin with polyethylene glycol or its derivatives and uses thereof
|
|
RU2440097C2
(ru)
|
2007-04-23 |
2012-01-20 |
Интарсия Терапьютикс, Инк. |
Способ лечения диабета ii типа и ожирения, осмотическое устройство для доставки и способ его изготовления
|
|
WO2008134425A1
(en)
|
2007-04-27 |
2008-11-06 |
Cedars-Sinai Medical Center |
Use of glp-1 receptor agonists for the treatment of gastrointestinal disorders
|
|
US7829664B2
(en)
|
2007-06-01 |
2010-11-09 |
Boehringer Ingelheim International Gmbh |
Modified nucleotide sequence encoding glucagon-like peptide-1 (GLP-1), nucleic acid construct comprising same for production of glucagon-like peptide-1 (GLP-1), human cells comprising said construct and insulin-producing constructs, and methods of use thereof
|
|
US9353170B2
(en)
|
2007-06-08 |
2016-05-31 |
Sanofi-Aventis Deutschland Gmbh |
Long-acting transient polymer conjugates of exendin
|
|
WO2008152403A1
(en)
|
2007-06-15 |
2008-12-18 |
Zealand Pharma A/S |
Glucagon analogues
|
|
WO2009009562A2
(en)
|
2007-07-10 |
2009-01-15 |
Eli Lilly And Company |
Glp-1-fc fusion protein formulation
|
|
WO2009020802A2
(en)
|
2007-08-03 |
2009-02-12 |
Eli Lilly And Company |
Treatment for obesity
|
|
CN101366692A
(zh)
|
2007-08-15 |
2009-02-18 |
江苏豪森药业股份有限公司 |
一种稳定的艾塞那肽制剂
|
|
US8816047B2
(en)
|
2007-08-30 |
2014-08-26 |
Cure DM Group Holdings, LLC |
Compositions and methods of using proislet peptides and analogs thereof
|
|
ES2532116T3
(es)
|
2007-09-05 |
2015-03-24 |
Novo Nordisk A/S |
Péptidos derivados con A-B-C-D y sus usos terapéuticos
|
|
WO2009035540A2
(en)
|
2007-09-07 |
2009-03-19 |
Ipsen Pharma S.A.S. |
Analogues of exendin-4 and exendin-3
|
|
KR20100090692A
(ko)
|
2007-10-24 |
2010-08-16 |
맨카인드 코포레이션 |
활성제의 전달
|
|
US8785396B2
(en)
|
2007-10-24 |
2014-07-22 |
Mannkind Corporation |
Method and composition for treating migraines
|
|
HUE025485T2
(en)
|
2007-10-24 |
2016-02-29 |
Mannkind Corp |
Respiratory dry powder formulation containing GLP-1 for use in the treatment of hyperglycemia and diabetes by pulmonary administration
|
|
ES2558155T3
(es)
|
2007-10-30 |
2016-02-02 |
Indiana University Research And Technology Corporation |
Compuestos que muestran actividad antagonista de glucacón y agonista de GLP-1
|
|
EP2217701B9
(en)
|
2007-10-30 |
2015-02-18 |
Indiana University Research and Technology Corporation |
Glucagon antagonists
|
|
ES2612736T3
(es)
|
2007-11-16 |
2017-05-18 |
Novo Nordisk A/S |
Composiciones farmacéuticas estables que comprenden liraglutida y degludec
|
|
EP2224945B1
(en)
|
2007-11-23 |
2012-05-16 |
Michael Rothkopf |
Methods of enhancing diabetes resolution
|
|
CN101444618B
(zh)
|
2007-11-26 |
2012-06-13 |
杭州九源基因工程有限公司 |
含有艾塞那肽的药物制剂
|
|
CN102026666B
(zh)
|
2007-12-11 |
2013-10-16 |
常山凯捷健生物药物研发（河北）有限公司 |
促胰岛素肽缀合物制剂
|
|
KR20100111682A
(ko)
|
2008-01-09 |
2010-10-15 |
사노피-아벤티스 도이칠란트 게엠베하 |
극히 지연된 시간-작용 프로필을 갖는 신규 인슐린 유도체
|
|
WO2009099763A1
(en)
|
2008-01-30 |
2009-08-13 |
Indiana University Research And Technology Corporation |
Ester-based peptide prodrugs
|
|
EP2237799B1
(en)
|
2008-02-01 |
2019-04-10 |
Ascendis Pharma A/S |
Prodrug comprising a self-cleavable linker
|
|
SG188126A1
(en)
|
2008-02-06 |
2013-03-28 |
Biocon Ltd |
Fermentation media comprising urea-like nitrogen sources and its use for the production of secondary metabolits, enzymes and recombinant proteias
|
|
WO2009114959A1
(zh)
|
2008-03-20 |
2009-09-24 |
中国人民解放军军事医学科学院毒物药物研究所 |
可注射用缓释药物制剂及其制备方法
|
|
CA2720864C
(en)
|
2008-04-07 |
2017-07-04 |
National Institute Of Immunology |
Compositions useful for the treatment of diabetes and other chronic disorder
|
|
WO2009137080A1
(en)
|
2008-05-07 |
2009-11-12 |
Merrion Research Iii Limited |
Compositions of gnrh related compounds and processes of preparation
|
|
WO2009143285A2
(en)
|
2008-05-21 |
2009-11-26 |
Amylin Pharmaceuticals, Inc. |
Exendins to lower cholestrol and triglycerides
|
|
US8329419B2
(en)
|
2008-05-23 |
2012-12-11 |
Amylin Pharmaceuticals, Llc |
GLP-1 receptor agonist bioassays
|
|
CA3153292A1
(en)
|
2008-06-13 |
2009-12-17 |
Mannkind Corporation |
A dry powder inhaler and system for drug delivery
|
|
US8485180B2
(en)
|
2008-06-13 |
2013-07-16 |
Mannkind Corporation |
Dry powder drug delivery system
|
|
BRPI0914889A2
(pt)
|
2008-06-17 |
2015-11-24 |
Otsuka Chemical Co Ltd |
peptídeo glp-1 adicionado de cadeia oligossacarídica
|
|
SG192405A1
(en)
|
2008-06-17 |
2013-08-30 |
Univ Indiana Res & Tech Corp |
Gip-based mixed agonists for treatment of metabolic disorders and obesity
|
|
KR20110039230A
(ko)
|
2008-06-17 |
2011-04-15 |
인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 |
생리학적 ｐＨ 완충액에서 강화된 용해도 및 안정성을 나타내는 글루카곤 유사체
|
|
CN102123723B
(zh)
|
2008-06-17 |
2016-05-25 |
印第安纳大学研究及科技有限公司 |
胰高血糖素/glp-1受体共激动剂
|
|
WO2009158704A2
(en)
|
2008-06-27 |
2009-12-30 |
Duke University |
Therapeutic agents comprising elastin-like peptides
|
|
US20110129522A1
(en)
|
2008-07-21 |
2011-06-02 |
Transpharma Medical Ltd. |
Transdermal system for extended delivery of incretins and incretn mimetic peptides
|
|
WO2010013012A2
(en)
|
2008-08-01 |
2010-02-04 |
Lund University Bioscience Ab |
Novel polypeptides and uses thereof
|
|
CN101670096B
(zh)
|
2008-09-11 |
2013-01-16 |
杭州九源基因工程有限公司 |
含有艾塞那肽的药物制剂
|
|
HUE048608T2
(hu)
|
2008-10-17 |
2020-08-28 |
Sanofi Aventis Deutschland |
Egy inzulin és egy GLP-1 agonista kombinációja
|
|
JP2012511586A
(ja)
|
2008-12-10 |
2012-05-24 |
グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー |
医薬組成物
|
|
DK2370460T3
(da)
|
2008-12-15 |
2014-08-04 |
Zealand Pharma As |
Glucagon analoger
|
|
JP5635529B2
(ja)
|
2008-12-15 |
2014-12-03 |
ジーランド ファーマ アクティーゼルスカブ |
グルカゴン類似体
|
|
ES2439499T3
(es)
|
2008-12-15 |
2014-01-23 |
Zealand Pharma A/S |
Análogos de glucagón
|
|
JP5635532B2
(ja)
|
2008-12-15 |
2014-12-03 |
ジーランド ファーマ アクティーゼルスカブ |
グルカゴン類似体
|
|
EP2376097A4
(en)
|
2008-12-19 |
2012-10-03 |
Univ Indiana Res & Tech Corp |
PEPTIDE PRODRUGS OF AMIDE-BASED GLUCAGON SUPERFAMILY
|
|
CN101538323B
(zh)
|
2009-01-13 |
2012-05-09 |
深圳翰宇药业股份有限公司 |
一种纯化艾塞那肽的方法
|
|
WO2010096052A1
(en)
|
2009-02-19 |
2010-08-26 |
Merck Sharp & Dohme Corp. |
Oxyntomodulin analogs
|
|
EP2403490B1
(en)
|
2009-03-04 |
2019-08-07 |
MannKind Corporation |
An improved dry powder drug delivery system
|
|
EP2403569B1
(en)
|
2009-03-05 |
2014-04-23 |
Sanofi-Aventis Deutschland GmbH |
Drug delivery device with retractable needle
|
|
US8642544B2
(en)
|
2009-04-01 |
2014-02-04 |
Amylin Pharmaceuticals, Llc |
N-terminus conformationally constrained GLP-1 receptor agonist compounds
|
|
WO2010118034A2
(en)
|
2009-04-06 |
2010-10-14 |
Board Of Regents, The University Of Texas System |
Cyclic peptide analogues for non-invasive imaging of pancreatic beta-cells
|
|
JP5727459B2
(ja)
|
2009-04-22 |
2015-06-03 |
アルテオゼン， インクＡｌｔｅｏｇｅｎ， Ｉｎｃ |
体内持続性を維持することにより体内半減期が増加したタンパク質またはペプチド融合体
|
|
CN101870728A
(zh)
|
2009-04-23 |
2010-10-27 |
派格生物医药(苏州)有限公司 |
新型Exendin变体及其缀合物
|
|
CN101559041B
(zh)
|
2009-05-19 |
2014-01-15 |
中国科学院过程工程研究所 |
粒径均一的多肽药物缓释微球或微囊制剂及制备方法
|
|
JP5698223B2
(ja)
|
2009-05-20 |
2015-04-08 |
サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング |
薬物送達デバイスにおける薬物含有カートリッジ用の栓
|
|
EP3189868B1
(en)
|
2009-05-20 |
2024-10-23 |
Sanofi-Aventis Deutschland GmbH |
A bung for drug containing cartridges in drug delivery devices comprising an electronic coding feature
|
|
EP2435061A4
(en)
|
2009-05-28 |
2013-03-27 |
Amylin Pharmaceuticals Inc |
DAMPING GLP-1 RECEPTOR AGONIST COMPOUNDS
|
|
JP2012529463A
(ja)
|
2009-06-11 |
2012-11-22 |
ノヴォ ノルディスク アー／エス |
２型糖尿病を治療するための、ｇｌｐ−１とｆｇｆ２１との組合せ
|
|
RU2012101274A
(ru)
|
2009-06-16 |
2013-07-27 |
Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн |
Соединения глюкагона, активные в отношении рецептора gip
|
|
JP5932642B2
(ja)
|
2009-07-02 |
2016-06-08 |
アンジオケム インコーポレーテッド |
多量体ペプチドコンジュゲートおよびその使用
|
|
KR101809024B1
(ko)
*
|
2009-07-13 |
2017-12-14 |
질랜드 파마 에이/에스 |
아실화 글루카곤 유사체
|
|
CN101601646B
(zh)
|
2009-07-22 |
2011-03-23 |
南京凯瑞尔纳米生物技术有限公司 |
治疗糖尿病的鼻腔滴剂及其制备方法
|
|
WO2011011675A1
(en)
|
2009-07-23 |
2011-01-27 |
Zelos Therapeutics, Inc. |
Pharmaceutically acceptable formulations/compositions for peptidyl drugs
|
|
NZ598021A
(en)
|
2009-07-31 |
2014-05-30 |
Sanofi Aventis Deutschland |
Prodrugs comprising an insulin linker conjugate
|
|
WO2011016030A1
(en)
*
|
2009-08-03 |
2011-02-10 |
Technion Research & Development Foundation Ltd. |
Hydrogen production by an autothermal heat exchanger packed-bed membrane gas reformer
|
|
WO2011017835A1
(en)
|
2009-08-11 |
2011-02-17 |
Nanjing University |
Preparation method of protein or peptide nanoparticles for in vivo drug delivery by unfolding and refolding
|
|
CN101993485B
(zh)
|
2009-08-20 |
2013-04-17 |
重庆富进生物医药有限公司 |
促胰岛素分泌肽类似物同源二聚体及其用途
|
|
US20120148586A1
(en)
|
2009-08-27 |
2012-06-14 |
Joyce Ching Tsu Chou |
Glucagon-like protein-1 receptor (glp-1r) agonists for treating autoimmune disorders
|
|
CA2774552A1
(en)
|
2009-09-30 |
2011-04-07 |
Glaxo Group Limited |
Drug fusions and conjugates with extended half life
|
|
US20110097386A1
(en)
|
2009-10-22 |
2011-04-28 |
Biodel, Inc. |
Stabilized glucagon solutions
|
|
US9610329B2
(en)
|
2009-10-22 |
2017-04-04 |
Albireo Pharma, Inc. |
Stabilized glucagon solutions
|
|
EP2490708B1
(en)
|
2009-10-22 |
2013-03-27 |
Biodel Inc. |
Stabilized glucagon solutions
|
|
EP2495255A4
(en)
|
2009-10-30 |
2013-05-15 |
Otsuka Chemical Co Ltd |
GLYCOSYLATED FORM OF AN ANTIGENIC GLP-1 ANALOG
|
|
EA021983B1
(ru)
|
2009-11-02 |
2015-10-30 |
Пфайзер Инк. |
Производные диоксабицикло[3.2.1]октан-2,3,4-триола
|
|
EP2496249B1
(en)
|
2009-11-03 |
2016-03-09 |
Amylin Pharmaceuticals, LLC |
Glp-1 receptor agonist for use in treating obstructive sleep apnea
|
|
RU2537239C2
(ru)
|
2009-11-13 |
2014-12-27 |
Санофи-Авентис Дойчланд Гмбх |
Фармацевтическая композиция, включающая агонист glp-1, инсулин и метионин
|
|
LT2498801T
(lt)
|
2009-11-13 |
2018-05-10 |
Sanofi-Aventis Deutschland Gmbh |
Farmacinė kompozicija, apimanti despro36eksendin-4(1-39)-lys6-nh2 ir metioniną
|
|
WO2011084459A1
(en)
|
2009-12-15 |
2011-07-14 |
Metabolic Solutions Development Company |
Ppar-sparing thiazolidinediones and combinations for the treatment of obesity and other metabolic diseases
|
|
AU2010331926B2
(en)
|
2009-12-15 |
2014-03-27 |
Cirius Therapeutics, Inc. |
PPAR-sparing thiazolidinediones and combinations for the treatment of neurodegenerative diseases
|
|
US8912335B2
(en)
|
2009-12-15 |
2014-12-16 |
Metabolic Solutions Development Company, Llc |
PPAR-sparing thiazolidinedione salts for the treatment of metabolic diseases
|
|
CN102753170A
(zh)
|
2009-12-15 |
2012-10-24 |
新陈代谢解决方案开发公司 |
治疗糖尿病及其它代谢性疾病的ppar节制的噻唑烷二酮和组合
|
|
WO2011080103A1
(en)
|
2009-12-16 |
2011-07-07 |
Novo Nordisk A/S |
Double-acylated glp-1 derivatives
|
|
WO2011075623A1
(en)
|
2009-12-18 |
2011-06-23 |
Latitude Pharmaceuticals, Inc. |
One - phase gel compos ition compri s ing phos pholi pids
|
|
WO2011075393A2
(en)
|
2009-12-18 |
2011-06-23 |
Indiana University Research And Technology Corporation |
Glucagon/glp-1 receptor co-agonists
|
|
CN101798588B
(zh)
|
2009-12-21 |
2015-09-09 |
上海仁会生物制药股份有限公司 |
Glp-1受体激动剂生物学活性测定方法
|
|
AR079344A1
(es)
|
2009-12-22 |
2012-01-18 |
Lilly Co Eli |
Analogo peptidico de oxintomodulina, composicion farmaceutica que lo comprende y uso para preparar un medicamento util para tratar diabetes no insulinodependiente y/u obesidad
|
|
JO2976B1
(en)
|
2009-12-22 |
2016-03-15 |
ايلي ليلي اند كومباني |
Axentomodulin polypeptide
|
|
JP2013517307A
(ja)
|
2010-01-20 |
2013-05-16 |
ジーランド ファーマ アクティーゼルスカブ |
心臓病の処置
|
|
MX2012008603A
(es)
|
2010-01-27 |
2013-01-25 |
Univ Indiana Res & Tech Corp |
Conjugados de antagonista de glucagon-agonista de gip y composiciones para el tratamiento de desordenes metabolicos y obesidad.
|
|
DK2531233T3
(en)
|
2010-02-01 |
2019-03-11 |
Sanofi Aventis Deutschland |
PATTERN HOLDER, PHARMACEUTICAL SUPPLY AND PROCEDURE FOR KEEPING A CARTRIDGE IN A CARTRIDGE
|
|
WO2011109784A1
(en)
|
2010-03-05 |
2011-09-09 |
Conjuchem, Llc |
Formulation of insulinotropic peptide conjugates
|
|
EP2552950A1
(en)
*
|
2010-03-26 |
2013-02-06 |
Novo Nordisk A/S |
Novel glucagon analogues
|
|
AR080592A1
(es)
|
2010-03-26 |
2012-04-18 |
Lilly Co Eli |
Peptido con actividad para el gip-r y glp-1-r, formulacion famaceutica que lo comprende, su uso para preparar un medicamento util para el tratamiento de diabetes mellitus y para inducir la perdida de peso
|
|
CA2797089A1
(en)
|
2010-05-13 |
2011-11-17 |
Indiana University Research And Technology Corporation |
Glucagon superfamily peptides exhibiting g protein-coupled receptor activity
|
|
WO2011143209A1
(en)
|
2010-05-13 |
2011-11-17 |
Indiana University Research And Technology Corporation |
Glucagon superfamily peptides exhibiting nuclear hormone receptor activity
|
|
AU2011202239C1
(en)
|
2010-05-19 |
2017-03-16 |
Sanofi |
Long-acting formulations of insulins
|
|
BR112012029280A2
(pt)
|
2010-05-20 |
2016-11-29 |
Glaxo Group Ltd |
variante de domínio variável único de imunoglobulina antialbumina sérica, imunoglobulina anti-sa, ligando multiespecífico, proteína de fusão, composição, ácido nucleico, vetor, célula hospedeira isolada, e, uso de uma variante, ligando multiespecífico ou proteína de fusão
|
|
US20130059093A1
(en)
|
2010-05-31 |
2013-03-07 |
Jtekt Corporation |
Method of producing coated member
|
|
EP2579435B1
(en)
|
2010-06-01 |
2016-11-30 |
Honda Motor Co., Ltd. |
Controller for dc/dc converter
|
|
US8263554B2
(en)
|
2010-06-09 |
2012-09-11 |
Amylin Pharmaceuticals, Inc. |
Methods of using GLP-1 receptor agonists to treat pancreatitis
|
|
CN101891823B
(zh)
|
2010-06-11 |
2012-10-03 |
北京东方百泰生物科技有限公司 |
一种Exendin-4及其类似物融合蛋白
|
|
US8636711B2
(en)
|
2010-06-14 |
2014-01-28 |
Legacy Emanuel Hospital & Health Center |
Stabilized glucagon solutions and uses therefor
|
|
RU2571331C1
(ru)
|
2010-06-21 |
2015-12-20 |
Маннкайнд Корпорейшн |
Системы и способы доставки сухих порошковых лекарств
|
|
UY33462A
(es)
*
|
2010-06-23 |
2012-01-31 |
Zealand Pharma As |
Analogos de glucagon
|
|
MX2012014576A
(es)
|
2010-06-24 |
2013-02-21 |
Univ Indiana Res & Tech Corp |
Profarmacos de peptido de la superfamilia de glucagon basado en amida.
|
|
WO2011162830A2
(en)
|
2010-06-24 |
2011-12-29 |
Biousian Biosystems, Inc. |
Glucagon-like peptide-1 glycopeptides
|
|
WO2011163473A1
(en)
|
2010-06-25 |
2011-12-29 |
Indiana University Research And Technology Corporation |
Glucagon analogs exhibiting enhanced solubility and stability in physiological ph buffers
|
|
WO2012012352A2
(en)
|
2010-07-19 |
2012-01-26 |
Amidebio, Llc |
Modified peptides and proteins
|
|
US20120046225A1
(en)
|
2010-07-19 |
2012-02-23 |
The Regents Of The University Of Colorado, A Body Corporate |
Stable glucagon formulations for the treatment of hypoglycemia
|
|
JP2013535471A
(ja)
|
2010-07-28 |
2013-09-12 |
アミリン・ファーマシューティカルズ，リミテッド・ライアビリティ・カンパニー |
安定化した領域を有するｇｌｐ−１受容体アゴニスト化合物
|
|
CN102397558B
(zh)
|
2010-09-09 |
2013-08-14 |
中国人民解放军军事医学科学院毒物药物研究所 |
Exendin-4类似物的定位聚乙二醇化修饰物及其用途
|
|
EP2438930A1
(en)
|
2010-09-17 |
2012-04-11 |
Sanofi-Aventis Deutschland GmbH |
Prodrugs comprising an exendin linker conjugate
|
|
EP2621538B1
(en)
|
2010-09-28 |
2015-12-16 |
Amylin Pharmaceuticals, LLC |
Engineered polypeptides having enhanced duration of action
|
|
WO2012059762A1
(en)
|
2010-11-03 |
2012-05-10 |
Arecor Limited |
Novel composition comprising glucagon
|
|
EP3536368B1
(en)
|
2010-11-09 |
2025-09-17 |
MannKind Corporation |
Dry powder inhaler comprising a serotonin receptor agonist and a diketopiperazine for treating migraines
|
|
EP2460552A1
(en)
|
2010-12-06 |
2012-06-06 |
Sanofi-Aventis Deutschland GmbH |
Drug delivery device with locking arrangement for dose button
|
|
CN102552883B
(zh)
|
2010-12-09 |
2014-02-19 |
天津药物研究院 |
一种多肽复合物、药物组合物、其制备方法和应用
|
|
RS60321B1
(sr)
|
2010-12-16 |
2020-07-31 |
Novo Nordisk As |
Čvrste kompozicije koje sadrže glp-1 agonist i so n-(8-(2- hidroksibenzoil)amino)kaprilne kiseline
|
|
EP2654767A4
(en)
|
2010-12-22 |
2014-05-21 |
Amylin Pharmaceuticals Inc |
GLP-1 RECEPTOR AGONISTS FOR ISLAND CELL TRANSPLANTATION
|
|
NZ612297A
(en)
|
2010-12-22 |
2015-10-30 |
Univ Indiana Res & Tech Corp |
Glucagon analogs exhibiting gip receptor activity
|
|
CN102532301B
(zh)
|
2010-12-31 |
2014-09-03 |
上海医药工业研究院 |
一类新型的Exendin-4类似物及其制备方法
|
|
US20120208755A1
(en)
|
2011-02-16 |
2012-08-16 |
Intarcia Therapeutics, Inc. |
Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
|
|
CN102100906A
(zh)
|
2011-02-18 |
2011-06-22 |
深圳翰宇药业股份有限公司 |
一种艾塞那肽的药用制剂及其制备方法
|
|
SG193389A1
(en)
|
2011-03-10 |
2013-10-30 |
Xeris Pharmaceuticals Inc |
Stable formulations for parenteral injection of peptide drugs
|
|
CN102718858B
(zh)
|
2011-03-29 |
2014-07-02 |
天津药物研究院 |
胰高血糖素样肽-1类似物单体、二聚体及其制备方法与应用
|
|
CN102718868A
(zh)
|
2011-03-30 |
2012-10-10 |
上海华谊生物技术有限公司 |
定点单取代聚乙二醇化Exendin类似物及其制备方法
|
|
US9790262B2
(en)
|
2011-04-05 |
2017-10-17 |
Longevity Biotech, Inc. |
Compositions comprising glucagon analogs and methods of making and using the same
|
|
EP2696897A2
(en)
|
2011-04-11 |
2014-02-19 |
Yeda Research and Development Co. Ltd. |
Albumin binding probes and drug conjugates thereof
|
|
WO2012150503A2
(en)
|
2011-05-03 |
2012-11-08 |
Zealand Pharma A/S |
Glu-glp-1 dual agonist signaling-selective compounds
|
|
CN102766204B
(zh)
|
2011-05-05 |
2014-10-15 |
天津药物研究院 |
胰高血糖素样肽-1突变体多肽及其制备方法和其应用
|
|
KR20240110072A
(ko)
|
2011-05-18 |
2024-07-12 |
메더리스 다이어비티즈, 엘엘씨 |
인슐린 저항성에 대한 개선된 펩티드 제약
|
|
EP2714069A4
(en)
|
2011-05-25 |
2015-06-24 |
Amylin Pharmaceuticals Llc |
LONG-TERM CONJUGATES WITH TWO HORMONES
|
|
UA113626C2
(xx)
|
2011-06-02 |
2017-02-27 |
|
Композиція для лікування діабету, що містить кон'югат інсуліну тривалої дії та кон'югат інсулінотропного пептиду тривалої дії
|
|
SG10201604564XA
(en)
|
2011-06-10 |
2016-07-28 |
Hanmi Science Co Ltd |
Novel oxyntomodulin derivatives and pharmaceutical composition for treating obesity comprising the same
|
|
CN103764673A
(zh)
|
2011-06-10 |
2014-04-30 |
北京韩美药品有限公司 |
葡萄糖依赖性促胰岛素多肽类似物、其药物组合物及应用
|
|
NZ618331A
(en)
|
2011-06-17 |
2016-04-29 |
Halozyme Inc |
Stable formulations of a hyaluronan-degrading enzyme
|
|
HRP20190265T1
(hr)
|
2011-06-17 |
2019-04-05 |
Hanmi Science Co., Ltd. |
Konjugat koji sadrži oksintomodulin i fragment imunoglobulina i njegova uporaba
|
|
BR112013032717A2
(pt)
|
2011-06-22 |
2017-01-24 |
Univ Indiana Res & Tech Corp |
coagonistas do receptor de glucagon/glp-1
|
|
US9156902B2
(en)
|
2011-06-22 |
2015-10-13 |
Indiana University Research And Technology Corporation |
Glucagon/GLP-1 receptor co-agonists
|
|
CN103906528A
(zh)
|
2011-06-24 |
2014-07-02 |
安米林药品有限责任公司 |
用glp-1受体激动剂的缓释制剂治疗糖尿病的方法
|
|
KR101357117B1
(ko)
|
2011-06-28 |
2014-02-06 |
비앤엘델리팜 주식회사 |
폴리에틸렌글라이콜 또는 이의 유도체로 페길화된 엑센딘-4 유사체, 이의 제조방법 및 이를 유효성분으로 함유하는 당뇨병 예방 또는 치료용 약학적 조성물
|
|
JP6396211B2
(ja)
|
2011-07-04 |
2018-09-26 |
インペリアル・イノベイションズ・リミテッド |
新規化合物及び摂食行動に対するそれらの効果
|
|
WO2013009545A1
(en)
|
2011-07-08 |
2013-01-17 |
Amylin Pharmaceuticals, Inc. |
Engineered polypeptides having enhanced duration of action with reduced immunogenicity
|
|
JP5950477B2
(ja)
|
2011-08-10 |
2016-07-13 |
アドシア |
少なくとも１種の基礎インスリンの注射溶液
|
|
EP2747832A4
(en)
|
2011-08-24 |
2015-01-07 |
Phasebio Pharmaceuticals Inc |
AGGREGATE FORMULATIONS FOR DELAYED RELEASE
|
|
CN103189389B
(zh)
|
2011-09-03 |
2017-08-11 |
深圳市健元医药科技有限公司 |
新的glp‑ⅰ类似物及其制备方法和用途
|
|
CN104093735B
(zh)
|
2011-09-23 |
2018-07-06 |
诺沃—诺迪斯克有限公司 |
新的胰高血糖素类似物
|
|
MX359329B
(es)
|
2011-10-28 |
2018-09-25 |
Sanofi Aventis Deutschland |
Una combinación farmacéutica para usarse en el tratamiento de un paciente que padece diabetes tipo 2.
|
|
CN102363633B
(zh)
|
2011-11-16 |
2013-11-20 |
天津拓飞生物科技有限公司 |
胰高血糖素样肽-1突变体多肽及其制备方法、药物组合物和其应用
|
|
WO2013074910A1
(en)
|
2011-11-17 |
2013-05-23 |
Indiana University Research And Technology Corporation |
Glucagon superfamily peptides exhibiting glucocorticoid receptor activity
|
|
HRP20200567T1
(hr)
|
2011-11-29 |
2020-06-26 |
Jurox Pty Ltd |
Stabilni injektabilni farmaceutski pripravci koji sadrže 2-hidroksipropil-beta-ciklodekstrin i alfaksalon
|
|
DE12858350T1
(de)
|
2011-12-16 |
2021-10-07 |
Modernatx, Inc. |
Modifizierte mrna zusammensetzungen
|
|
ES2623786T3
(es)
|
2011-12-22 |
2017-07-12 |
Pfizer Inc. |
Procedimiento de purificación de una muestra de anticuerpo H38C2
|
|
IN2014CN04401A
(enExample)
|
2011-12-23 |
2015-09-04 |
Zealand Pharma As |
|
|
EP2797585A4
(en)
|
2011-12-29 |
2015-10-07 |
Latitude Pharmaceuticals Inc |
STABILIZED GLUCAGONNANOULULSIONS
|
|
CN113730555A
(zh)
|
2012-01-09 |
2021-12-03 |
阿道恰公司 |
Ph为7且至少含pi为5.8至8.5之基础胰岛素和取代共聚(氨基酸)的可注射溶液
|
|
EP2844269A4
(en)
|
2012-03-28 |
2016-01-06 |
Amylin Pharmaceuticals Llc |
TRANSMUCOSAL ADMINISTRATION OF MANIPULATED POLYPEPTIDES
|
|
WO2013148871A1
(en)
|
2012-03-28 |
2013-10-03 |
Amylin Pharmaceuticals, Llc |
Engineered polypeptides
|
|
CN104411338A
(zh)
|
2012-04-02 |
2015-03-11 |
现代治疗公司 |
用于产生与人类疾病相关的生物制剂和蛋白质的修饰多核苷酸
|
|
HK1206601A1
(en)
|
2012-04-02 |
2016-01-15 |
Moderna Therapeutics, Inc. |
Modified polynucleotides for the production of biologics and proteins associated with human disease
|
|
CN102649947A
(zh)
|
2012-04-20 |
2012-08-29 |
无锡和邦生物科技有限公司 |
一种用于测定glp-1及其功能类似物生物活性的细胞株及其应用
|
|
US20150111246A1
(en)
|
2012-04-24 |
2015-04-23 |
Astrazeneca Pharmaceuticals Lp |
Site-specific enzymatic modification of exendins and analogs thereof
|
|
US20130289241A1
(en)
|
2012-04-26 |
2013-10-31 |
Shanghai Ambiopharm, Inc. |
Method for preparing exenatide
|
|
US8901484B2
(en)
|
2012-04-27 |
2014-12-02 |
Sanofi-Aventis Deutschland Gmbh |
Quantification of impurities for release testing of peptide products
|
|
WO2013182217A1
(en)
|
2012-04-27 |
2013-12-12 |
Sanofi-Aventis Deutschland Gmbh |
Quantification of impurities for release testing of peptide products
|
|
CA2872315A1
(en)
|
2012-05-03 |
2013-11-07 |
Zealand Pharma A/S |
Glucagon-like-peptide-2 (glp-2) analogues
|
|
AU2013255751B2
(en)
|
2012-05-03 |
2017-10-05 |
Zealand Pharma A/S |
GIP-GLP-1 dual agonist compounds and methods
|
|
EP2664374A1
(en)
|
2012-05-15 |
2013-11-20 |
F. Hoffmann-La Roche AG |
Lysin-glutamic acid dipeptide derivatives
|
|
CN103421094A
(zh)
|
2012-05-24 |
2013-12-04 |
上海医药工业研究院 |
一种具有epo类似活性的多肽化合物
|
|
WO2013177565A1
(en)
|
2012-05-25 |
2013-11-28 |
Amylin Pharmaceuticals, Llc |
Insulin-pramlintide compositions and methods for making and using them
|
|
AR091422A1
(es)
|
2012-06-14 |
2015-02-04 |
Sanofi Sa |
Analogos peptidicos de la exendina 4
|
|
CA2877358A1
(en)
|
2012-06-21 |
2013-12-27 |
Indiana University Research And Technology Corporation |
Glucagon analogs exhibiting gip receptor activity
|
|
RS57347B1
(sr)
|
2012-06-21 |
2018-08-31 |
Univ Indiana Res & Tech Corp |
Analozi glukagona koji ispoljavaju aktivnost gip receptora
|
|
CN104619369B
(zh)
|
2012-07-12 |
2018-01-30 |
曼金德公司 |
干粉药物输送系统和方法
|
|
CN109456400A
(zh)
|
2012-07-23 |
2019-03-12 |
西兰制药公司 |
胰高血糖素类似物
|
|
AR094821A1
(es)
|
2012-07-25 |
2015-09-02 |
Hanmi Pharm Ind Co Ltd |
Formulación líquida de un conjugado de péptido insulinotrópico de acción prolongada
|
|
AR092862A1
(es)
|
2012-07-25 |
2015-05-06 |
Hanmi Pharm Ind Co Ltd |
Formulacion liquida de insulina de accion prolongada y un peptido insulinotropico y metodo de preparacion
|
|
KR101968344B1
(ko)
|
2012-07-25 |
2019-04-12 |
한미약품 주식회사 |
옥신토모듈린 유도체를 포함하는 고지혈증 치료용 조성물
|
|
EP2934562A1
(en)
|
2012-08-14 |
2015-10-28 |
Wockhardt Limited |
Pharmaceutical microparticulate compositions of polypeptides
|
|
US20150258198A1
(en)
|
2012-08-14 |
2015-09-17 |
Wockhardt Limited |
Pharmaceutical microparticulate compositions of polypeptides
|
|
CN102816244A
(zh)
|
2012-08-23 |
2012-12-12 |
无锡和邦生物科技有限公司 |
一种Exendin-4肽与人血清白蛋白HSA的融合蛋白及其制备方法
|
|
CN102827270A
(zh)
|
2012-09-13 |
2012-12-19 |
无锡和邦生物科技有限公司 |
一种聚乙二醇化艾塞那肽衍生物及其用途
|
|
TWI608013B
(zh)
|
2012-09-17 |
2017-12-11 |
西蘭製藥公司 |
升糖素類似物
|
|
EP2895506A1
(en)
|
2012-09-17 |
2015-07-22 |
Imperial Innovations Limited |
Peptide analogues of glucagon and glp1
|
|
AR092873A1
(es)
|
2012-09-26 |
2015-05-06 |
Cadila Healthcare Ltd |
Peptidos como agonistas triples de los receptores de gip, glp-1 y glugagon
|
|
UA116217C2
(uk)
|
2012-10-09 |
2018-02-26 |
Санофі |
Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
|
|
KR101993393B1
(ko)
|
2012-11-06 |
2019-10-01 |
한미약품 주식회사 |
옥신토모듈린 유도체를 포함하는 당뇨병 또는 비만성 당뇨병 치료용 조성물
|
|
TWI816739B
(zh)
|
2012-11-06 |
2023-10-01 |
南韓商韓美藥品股份有限公司 |
包含調酸素及免疫球蛋白片段之蛋白質接合物的液態製劑
|
|
US11065304B2
(en)
|
2012-11-20 |
2021-07-20 |
Mederis Diabetes, Llc |
Peptide pharmaceuticals for insulin resistance
|
|
TWI674270B
(zh)
|
2012-12-11 |
2019-10-11 |
英商梅迪繆思有限公司 |
用於治療肥胖之升糖素與glp-1共促效劑
|
|
HRP20181300T1
(hr)
|
2012-12-21 |
2018-10-05 |
Sanofi |
Derivati eksendina-4 kao dvostruki glp1/gip- ili trostruki glp1/gip/glukagon agonisti
|
|
CN103908657A
(zh)
|
2012-12-31 |
2014-07-09 |
复旦大学附属华山医院 |
胰升糖素样肽-1类似物在制备眼科疾病药物中的用途
|
|
BR112015023071A2
(pt)
|
2013-03-14 |
2017-07-18 |
Univ Indiana Res & Tech Corp |
conjugados de insulina-incretina
|
|
WO2014140222A1
(en)
|
2013-03-14 |
2014-09-18 |
Medimmune Limited |
Pegylated glucagon and glp-1 co-agonists for the treatment of obesity
|
|
US20160058881A1
(en)
|
2013-03-15 |
2016-03-03 |
Indiana University Research And Technology Corporation |
Prodrugs with prolonged action
|
|
MY174727A
(en)
|
2013-04-18 |
2020-05-11 |
Novo Nordisk As |
Stable, protracted glp-1/glucagon receptor co-agonists for medical use
|
|
JP2014227368A
(ja)
|
2013-05-21 |
2014-12-08 |
国立大学法人帯広畜産大学 |
糖尿病および高血糖状態の処置のためのグルカゴンアナログ
|
|
CN103304660B
(zh)
|
2013-07-12 |
2016-08-10 |
上海昂博生物技术有限公司 |
一种利拉鲁肽的合成方法
|
|
CN103405753B
(zh)
|
2013-08-13 |
2016-05-11 |
上海仁会生物制药股份有限公司 |
稳定的促胰岛素分泌肽水针药物组合物
|
|
AP2016009212A0
(en)
|
2013-10-17 |
2016-05-31 |
Zealand Pharma As |
Acylated glucagon analogues
|
|
US9988429B2
(en)
|
2013-10-17 |
2018-06-05 |
Zealand Pharma A/S |
Glucagon analogues
|
|
AU2014345570B2
(en)
|
2013-11-06 |
2019-01-24 |
Zealand Pharma A/S |
Glucagon-GLP-1-GIP triple agonist compounds
|
|
EP3080149A1
(en)
|
2013-12-13 |
2016-10-19 |
Sanofi |
Dual glp-1/glucagon receptor agonists
|
|
TW201609796A
(zh)
|
2013-12-13 |
2016-03-16 |
賽諾菲公司 |
非醯化之艾塞那肽－４（ｅｘｅｎｄｉｎ－４）胜肽類似物
|
|
WO2015086731A1
(en)
|
2013-12-13 |
2015-06-18 |
Sanofi |
Exendin-4 peptide analogues as dual glp-1/glucagon receptor agonists
|
|
WO2015086732A1
(en)
|
2013-12-13 |
2015-06-18 |
Sanofi |
Exendin-4 peptide analogues
|
|
WO2015086728A1
(en)
|
2013-12-13 |
2015-06-18 |
Sanofi |
Exendin-4 peptide analogues as dual glp-1/gip receptor agonists
|
|
EP3080154B1
(en)
|
2013-12-13 |
2018-02-07 |
Sanofi |
Dual glp-1/gip receptor agonists
|
|
CN103665148B
(zh)
|
2013-12-17 |
2016-05-11 |
中国药科大学 |
一种可口服给药的降糖多肽及其制法和用途
|
|
CN103980358B
(zh)
|
2014-01-03 |
2016-08-31 |
杭州阿诺生物医药科技股份有限公司 |
一种制备利拉鲁肽的方法
|
|
AU2015205624A1
(en)
|
2014-01-09 |
2016-07-14 |
Sanofi |
Stabilized pharmaceutical formulations of insulin analogues and/or insulin derivatives
|
|
CN111658604A
(zh)
|
2014-01-09 |
2020-09-15 |
赛诺菲 |
胰岛素类似物和/或胰岛素衍生物的稳定化不含甘油的药物制剂
|
|
GB201404002D0
(en)
|
2014-03-06 |
2014-04-23 |
Imp Innovations Ltd |
Novel compounds
|
|
TW201625670A
(zh)
|
2014-04-07 |
2016-07-16 |
賽諾菲公司 |
衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑
|
|
TW201625669A
(zh)
|
2014-04-07 |
2016-07-16 |
賽諾菲公司 |
衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
|
|
TW201625668A
(zh)
|
2014-04-07 |
2016-07-16 |
賽諾菲公司 |
作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物
|
|
US9932381B2
(en)
|
2014-06-18 |
2018-04-03 |
Sanofi |
Exendin-4 derivatives as selective glucagon receptor agonists
|
|
CN106519015B
(zh)
|
2014-09-23 |
2020-04-17 |
深圳市图微安创科技开发有限公司 |
胃泌酸调节素类似物
|
|
CN107108713A
(zh)
|
2014-10-10 |
2017-08-29 |
诺和诺德股份有限公司 |
稳定的基于glp‑1的glp‑1/胰高血糖素受体共激动剂
|
|
EA201790914A1
(ru)
|
2014-10-24 |
2017-08-31 |
Мерк Шарп И Доум Корп. |
Коагонисты рецепторов глюкагона и glp-1
|
|
WO2016198604A1
(en)
|
2015-06-12 |
2016-12-15 |
Sanofi |
Exendin-4 derivatives as dual glp-1 /glucagon receptor agonists
|
|
WO2016198624A1
(en)
|
2015-06-12 |
2016-12-15 |
Sanofi |
Exendin-4 derivatives as trigonal glp-1/glucagon/gip receptor agonists
|